BCL2 and B-cell chronic lymphocytic leukemia: As with the overall priming, relapsed/refractory status or TP53 mutations (Supplementary Fig. 3) were not sufficient to drive the loss of BCL-2 dependence, which occurred only in transformed disease (P < 0.0001 when comparing relapsed/refractory CLL with RS).